S1PR1 and myeloid sarcoma: While fingolimod (FTY720), the first approved sphingosine-1-phosphate receptor (S1PR) modulator for treatment of MS, targets cells expressing S1P receptors 1, 3, 4 and 5 (12), ozanimod is more selective, only targeting S1PR1 and S1PR5 (16).